Thèse D.GATEFF

43 AIZMAN O, BRIMAR H, UHLEN P et coll. Anatomical and physiological evidence for D1 and D2 dopamin
receptor colonization in neostriatal neurons. Nat Neurosci 200 ; 3 : 226-230
44 SMITH Y, KIEVAL JZ, Anatomy of the dopamine system in the basal ganglia. TINS 2000 ; 23 (suppl) : S28-
S33
45 BARTABET R, TURNER R, CHOCKAN V et coll. Dopaminergicneurons intrinsic to the primate striatum. J
Neuroscience 1997; 17 : 6761-6768
46 DEFEBVRE L. VERIN M. Op. cit
47 VIALLET F, GAYRAUD D, BONNEFOI-KYRIACOU B et coll. Aspects cliniques et thérapeutiques de la
maladie de Parkinson. Encycl Med Chir Elsevier SAS Paris, Neurologie, 17-060-A-50, 2001
48 DEFEBVRE L. VERIN M. Op. cit
49 VIALLET F. Op. cit.
50 LEVY R, HAZRATI LN, HERRERO MT et coll. Re-evaluation of the functional anatomy of the basal ganglia
in normal and Parkinson states. Neuroscience 1997 ; 76 : 335-343
51 NIEOULLON A. Dopamine and regulation of cognition and attention. Prog Neurobiol 2002 ; 67 : 53-83
52 BORAUD T, BEZARD E, BIOULAC B, GROSS CE. From single extracellular unit recording in
experimental and human parkinsonism to the development of a functinal concept of the role played by the
basal ganglia in motor control. Prog Neurobiol 2002 ; 66 : 265-283
53 SCHULTZ W. Predictive reward signal of dopamine neurons . J Neurophysiol 1998 ; 80 : 1-27
54 BAR-GAD I, BERGMAN H. Stepping out of the box : Information processing in the neural networks of the
basal ganglia. Curr Opin Neurobiol 2001 ; 11 : 689-695
55 BIOULAC B, BURBAUD P, CAZALETS JR, GROSS C. Fonctions motrices. Encycl Med Chir Elsevier SAS
Paris, Neurobiologie, 17-02-D-10, 2004
56 BERGMAN H, FEINGOLD A, NINI A et coll. Physiological aspects of information processing in the basal
ganglia of normal and parkinsonian primates. TINS 1998 ; 21 : 32-38
57 OBESO JA. Op. cit.
58 VIALLET F. Op. cit.
59 MARSDEN CD. The mysterious motor functionof the basal ganglia : the Robert Wartemberg lecture.
Neurology 1982 ; 32 : 514-539
60 DEFEBVRE L. VERIN M. Op. cit
61 NIEOULLON A. Op.cit
62 EBADI M. PFEIFFER RF. Parkinson s disease. Ed CRC Press, 2004 ISBN 0-8493-1590-5
63 PURVES D,AUGUSTINE GJ, FITZPATRICK D, HAL WC, LAMANTINA AS, MCNAMARA JO, WHITE
LE ; Neuroscience. Sunderland, MA: Sinauer Associates, Inc.. pp. 462-464. ISBN 0878936971. (2008)
64 Ibid.
65 HORNYKIEWICZ O. Biochemical aspects of Parkinson mical aspects of Parkinson s disease. Neurology
1998 : 51 : S2-S9
66 HIRSCH E, GRAYBIEL AM, AGID YA, Melanized dopaminergic neurons are differencially susceptible to
degeneration in Parkinson s disease. Nature 1988 ; 334 : 345-348
67 Ubiquitin Immunochemistry as a Diagnostic Aid for Community Pathologists Evaluating Patients Who Have
DementiaCharleen T Chu, James L Caruso, Thomas J Cummings, John Ervin, Carlyn Rosenberg and Christine
M Hulette
68 Loeffler et al. Journal of Neuroinflammation 2006 3:29 doi:10.1186/1742-2094-3-29
69 DEFEBVRE L, VERIN M. Op. cit.
70 MAROTEAUX L et al. Synuclein : a neuron-specific protein localized to the nucleus and presynaptic nerv
terminal. J Neurosci. 1998 ; 8 : 2804.
71 SPILLANTINI MG et al. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNBC) genes to
chromosome 4q21 and 5q35. Genomics, 1995 ; 27 : 379
72 PEREZ RG et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neuroscience. 2002
; 22 : 3090.
73 EBADI M. Op. cit.
74 ABELIOVICH A, SCHMITZ Y, FARINAS I et coll. Mice lacking alpha-synuclein display functional deficits
in the nigrostriatal dopamine system. Neuron 200 ; 25 : 239-252
75 GOEDERT M. Op. cit.
76 ZAGNOLI F. Op. cit. P14
77 Ibid. P8
78 DEFEBVRE L, DUJARDIN K. Neuropsychologie de la maladie de Parkinson et des syndromes apparentés.
Paris, Monographie du neurologue Masson 2006.
79 DAVIES GC, WILLIAMS AC, MARKEY SP. Chronic Parkinsonism secondary to intravenous injection of
meperidine analogues. Psychiatry Res 1979 ; 1 : 249-254
257